Sanofi to pay Regeneron up to $8B to add four long-acting antibodies to Dupixent partnership

Sanofi is expanding its alliance with Regeneron to add four long-acting antibodies under their Dupixent partnership, paying $1B upfront with up to $8B in total milestones, with costs and profits shared equally.

Detected & updated continuously · Source: Nebula